{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T09:22:13Z","timestamp":1738488133311,"version":"3.35.0"},"reference-count":27,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2025,1,31]]},"DOI":"10.1536\/ihj.24-169","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:14:03Z","timestamp":1738275243000},"page":"137-143","source":"Crossref","is-referenced-by-count":0,"title":["Esaxerenone Attenuates Cardiac Hypertrophy in a Pressure Overload Model in Mice"],"prefix":"10.1536","volume":"66","author":[{"given":"Ou","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"},{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 2018; 15: 387-407.","DOI":"10.1038\/s41569-018-0007-y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Parati G, Esler M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058-66.","DOI":"10.1093\/eurheartj\/ehs041"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Murphy SP, Ibrahim NE, Januzzi JL. Heart Failure with Reduced Ejection Fraction: A Review. J Am Med Assoc 2020; 324: 488-504.","DOI":"10.1001\/jama.2020.10262"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsutsui H, Ide T, Ito H, <i>et al<\/i>. JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. J Card Fail 2021; 27: 1404-44.","DOI":"10.1016\/j.cardfail.2021.04.023"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-73.","DOI":"10.1038\/nrneph.2010.30"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ayuzawa N, Nagase M, Ueda K, <i>et al<\/i>. Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury. Hypertension 2016; 67: 99-106.","DOI":"10.1161\/HYPERTENSIONAHA.115.06054"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Agarwal R, Kolkhof P, Bakris G, <i>et al<\/i>. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42: 152-61.","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Matsui Y, Jia N, Okamoto H, <i>et al<\/i>. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43: 1195-201.","DOI":"10.1161\/01.HYP.0000128621.68160.dd"},{"key":"10","unstructured":"10. Ma J, Zhang H, Guo H, Xu Y. Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats. Am J Transl Res 2014; 6: 809-19."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zannad F, Gattis Stough W, Rossignol P, <i>et al<\/i>. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice. Eur Heart J 2012; 33: 2782-95.","DOI":"10.1093\/eurheartj\/ehs257"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. J Hum Hypertens 2021; 35: 148-56.","DOI":"10.1002\/ddr.21760"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006; 47: 887-93.","DOI":"10.1161\/01.HYP.0000215207.54689.31"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Suetomi T, Willeford A, Brand CS, <i>et al<\/i>. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+\/Calmodulin-Dependent Protein Kinase II \u03b4 Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. Circulation 2018; 138: 2530-44.","DOI":"10.1161\/CIRCULATIONAHA.118.034621"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Higashikuni Y, Liu W, Numata G, <i>et al<\/i>. NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload. Circulation 2023; 147: 338-55.","DOI":"10.1161\/CIRCULATIONAHA.122.060860"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hofstetter C, Flondor M, Boost KA, <i>et al<\/i>. A brief exposure to isoflurane (50 seconds) significantly impacts on plasma cytokine levels in endotoxemic rats. Int Immunopharmacol 2005; 5: 1519-22.","DOI":"10.1016\/j.intimp.2005.04.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bedirli N, Demirtas CY, Akkaya T, <i>et al<\/i>. Volatile anesthetic preconditioning attenuated sepsis induced lung inflammation. J Surg Res 2012; 178: e17-23.","DOI":"10.1016\/j.jss.2011.12.037"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: Clinical relevance for resistant hypertension. Am J Hypertens 2012; 25: 514-23.","DOI":"10.1038\/ajh.2011.245"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Nagata K, Obata K, Xu J, <i>et al<\/i>. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-64.","DOI":"10.1161\/01.HYP.0000203772.78696.67"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arai K, Homma T, Morikawa Y, <i>et al<\/i>. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol 2015; 761: 226-34.","DOI":"10.1016\/j.ejphar.2015.06.015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Boulaksil M, Noorman M, Engelen MA, <i>et al<\/i>. Longitudinal arrhythmogenic remodelling in a mouse model of longstanding pressure overload. Neth Heart J 2010; 18: 509-15.","DOI":"10.1007\/BF03091824"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Qu J, Volpicelli FM, Garcia LI, <i>et al<\/i>. Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res 2009; 104: 365-71.","DOI":"10.1161\/CIRCRESAHA.108.184044"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Arai K, Morikawa Y, Ubukata N, Sugimoto K. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res 2020; 43: 1204-13.","DOI":"10.1038\/s41440-020-0495-0"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 2019; 65: 70-99.","DOI":"10.1016\/j.mam.2018.07.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Grune J, Benz V, Brix S, <i>et al<\/i>. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol 2016; 67: 402-11.","DOI":"10.1097\/FJC.0000000000000366"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Langenickel T, Pagel I, H\u00f6hnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol 2000; 278: H1500-6.","DOI":"10.1152\/ajpheart.2000.278.5.H1500"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Yasue H, Yoshimura M, Sumida H, <i>et al<\/i>. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.","DOI":"10.1161\/01.CIR.90.1.195"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-169\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:11:18Z","timestamp":1738383078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-169\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.24-169","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"type":"print","value":"1349-2365"},{"type":"electronic","value":"1349-3299"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"24-169"}}